8-K: BridgeBio Reports Strong Q4/FY25 Revenue, Multiple Phase 3 Successes

BridgeBio Pharma announced robust fourth quarter and full year 2025 financial results, driven by Attruby sales and positive Phase 3 trial readouts for three pipeline assets.

Summary

• Total revenues, net, for the fourth quarter of 2025 were $154.2 million, a significant increase from $5.9 million in the same period of 2024.
• Full year 2025 total revenues, net, reached $502.1 million, up from $221.9 million in 2024.
• Net product revenue from Attruby was $146.0 million in Q4 2025 and $362.4 million for the full year 2025.
• As of February 20, 2026, Attruby had 7,804 unique patient prescriptions written by 1,856 unique prescribers.
• The PROPEL 3 Phase 3 trial for oral infigratinib in achondroplasia successfully met its primary endpoint (p<0.0001), showing a mean treatment difference of +2.10 cm/year in absolute height velocity (AHV) versus placebo at Week 52.
• Topline results from PROPEL 3 also showed the first statistically significant improvements in body proportionality in achondroplasia.
• Positive interim Phase 3 FORTIFY results for BBP-418 in LGMD2I/R9 demonstrated a statistically significant and clinically meaningful 2.6-point NSAD improvement versus placebo at 12 months.
• Phase 3 CALIBRATE results for encaleret in ADH1 successfully achieved all pre-specified primary and key secondary efficacy endpoints.
• Cash, cash equivalents, and marketable securities totaled $587.5 million as of December 31, 2025.
• The company completed the issuance of $632.5 million aggregate principal amount of 2033 convertible notes in January 2026.
• Net loss attributable to common stockholders was $192.9 million ($1.00 per share) for Q4 2025 and $724.9 million ($3.78 per share) for the full year 2025.
• Operating costs and expenses for the full year 2025 increased to $1.025 billion from $814.9 million in 2024, primarily due to investments in the commercial launch and ongoing activities of Attruby.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong commercial performance of Attruby and multiple successful late-stage clinical trial readouts, which significantly de-risk the pipeline and set the stage for future product launches, despite increased operating costs and an overall net loss for the full year.

Positives

• Total revenues, net, for Q4 2025 ($154.2 million) and full year 2025 ($502.1 million) showed substantial growth compared to prior periods, driven by Attruby sales.
• Attruby demonstrated strong commercial momentum with $146.0 million in Q4 net product revenue and 35% quarter-over-quarter growth, exceeding expectations for patient persistence.
• Attruby continues to show clinical differentiation as a first-choice therapy in ATTR-CM with 90% TTR stabilization and rapid clinical benefit observed within 1 month.
• Three positive Phase 3 trial readouts were achieved in just over three months for infigratinib (achondroplasia), BBP-418 (LGMD2I/R9), and encaleret (ADH1), validating the company's drug development model.
• PROPEL 3 for oral infigratinib met its primary endpoint (p<0.0001) and showed the first statistically significant improvements in body proportionality in achondroplasia.
• BBP-418's FORTIFY interim analysis demonstrated statistically significant and clinically meaningful NSAD improvement, leading to an FDA recommendation for traditional approval.
• Encaleret's CALIBRATE study successfully met all primary and key secondary efficacy endpoints, and a pre-NDA meeting with the FDA was successfully completed.
• The company's cash, cash equivalents, and marketable securities of $587.5 million as of December 31, 2025, combined with the $632.5 million convertible notes issued in January 2026, position it to fund planned operations.
• The reauthorization of the Rare Pediatric Review Voucher (PRV) program makes BBP-418, BBP-812, and infigratinib potentially eligible for PRVs upon approval.
• The company's unique model for sustainable drug development was published in a peer-reviewed manuscript, highlighting its effectiveness in reducing asset-level risk and improving clinical success rates.

Negatives

• The net loss attributable to common stockholders for the full year 2025 increased to $724.9 million from $535.8 million in 2024.
• The net loss per share for the full year 2025 increased to $3.78 from $2.88 in 2024.
• Operating costs and expenses significantly increased for both Q4 2025 ($293.7 million vs. $231.9 million in Q4 2024) and full year 2025 ($1.025 billion vs. $814.9 million in FY 2024), primarily due to commercial launch investments for Attruby.
• Cash, cash equivalents, and marketable securities decreased by $93.6 million from December 31, 2024, to December 31, 2025, primarily due to $445.9 million in net cash used in operating activities and $459.0 million in debt repayment.
• License and services revenue decreased for the full year 2025 to $128.3 million from $218.8 million in 2024.
• Noncash interest expense on deferred royalty obligations increased substantially to $125.1 million for the full year 2025 from $8.3 million in 2024.
• Net loss from equity method investments increased to $72.6 million for the full year 2025 from $31.2 million in 2024.

Risks

• Initial and ongoing data from preclinical studies and clinical trials may not be indicative of final data.
• The potential size of the target patient populations for product candidates may not be as large as anticipated.
• The design and success of ongoing and planned clinical trials are subject to uncertainties.
• Future regulatory filings, approvals, and/or sales are not guaranteed.
• The FDA or other regulatory agencies may not agree with the company's regulatory approval strategies, clinical trial designs, conduct, methodologies, or the sufficiency of data submitted.
• The continuing success of collaborations is not assured.
• The company's ability to obtain additional funding, including through less dilutive sources of capital than equity financings, is a factor.
• Potential volatility in the company's share price exists.
• Current macroeconomic and geopolitical events, including hostilities in Ukraine and in Israel and the Gaza Strip, increasing rates of inflation, and changing interest rates, could impact business operations and expectations.

Future Outlook

BridgeBio anticipates submitting NDAs to the FDA for BBP-418 (LGMD2I/R9) and encaleret (ADH1) in the first half of 2026, with U.S. launches projected for late 2026/early 2027. An NDA for infigratinib (achondroplasia) is planned for the second half of 2026, targeting an early to mid-2027 launch. The company also plans to initiate a Phase 3 study for encaleret in chronic hypoparathyroidism and further clinical studies for BBP-418 in pediatric and other LGMD forms, and for infigratinib in hypochondroplasia.

Management Comments

• "As we close our first decade at BridgeBio, we're reflecting on just how far we've come – from a bold idea about a new type of biotech rooted in a hub-and-spoke model to a company with incredible commercial strength and multiple late-stage successes. In a little over three months, we've delivered three successful Phase 3 readouts, a testament to the rigor of our science, the dedication of our teams, and the trust of the patients and physicians we serve. In all, we hope this leads to 6 approved products as our first decade draws to a close. I am excited not only to live up to our responsibilities against these assets but further to see if we can do even better." Neil Kumar, Ph.D., Co-Founder and CEO.
• "2025 reflected strong commercial momentum for Attruby and an important step forward as we advance three additional medicines toward potential commercialization. Attruby delivered 35% quarter-over-quarter growth in net product revenue in Q4, driven by its differentiated profile as the only near-complete stabilizer on the market, continued prescribing growth, repeat use, and patient persistence that has exceeded our expectations. As we prepare for the potential launches of BBP-418, encaleret, and infigratinib, we are intentionally applying the learnings established with Attruby. When successful, these approvals will bring BridgeBio to achieving six approved medicines, which marks a significant milestone for our platform and positions us to extend our impact to even more patients with genetic conditions." Matt Outten, Chief Commercial Officer.

Industry Context

StockSavvy.ai notes that BridgeBio's "hub-and-spoke" model for drug development, emphasizing genetic validation and capital efficiency, is gaining recognition, as evidenced by its publication in a peer-reviewed journal and case studies at Harvard and MIT. This approach aims to de-risk drug development in the challenging rare disease space, potentially offering a more sustainable path to bringing multiple therapies to market compared to traditional large pharma models. The focus on genetic conditions aligns with a broader industry trend towards precision medicine.

Comparison to Industry Standards

• Attruby's 90% TTR stabilization is presented as the greatest on the market, suggesting a strong competitive profile against other ATTR-CM therapies.
• The rapid benefit on clinical outcomes observed within 1 month for Attruby highlights a potentially superior speed of action compared to other treatments.
• The achievement of three positive Phase 3 readouts in just over three months for rare genetic conditions (achondroplasia, LGMD2I/R9, ADH1) demonstrates exceptional R&D productivity and clinical execution, which is a high benchmark in the biopharmaceutical industry, especially for a company of BridgeBio's size.
• BBP-418, if approved, could be the first approved therapy for any form of LGMD, setting a new standard in this underserved area.
• Encaleret, if approved, would be the first therapy specifically indicated for ADH1, addressing a significant unmet medical need.
• Infigratinib, if approved, would be the first oral therapy option for children with achondroplasia or hypochondroplasia, offering a significant convenience advantage over injectable therapies.

Management Changes

Related Party Transactions

• Net proceeds of $297.0 million were received from the execution of the Royalty Interest Purchase and Sale Agreement with HealthCare Royalty, a related party, and Blue Owl Capital in June 2025.
• Noncash interest expense on deferred royalty obligations included related party amounts of $(5,383) for the three months ended December 31, 2025, and $(10,944) for the year ended December 31, 2025.
• Accrued and other current liabilities included a related party amount of $2,003 as of December 31, 2025.
• Deferred royalty obligations, net, included a related party amount of $204,650 as of December 31, 2025.
• Repayments of deferred royalty obligations included a related party amount of $(2,295) for the year ended December 31, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth and multiple successful Phase 3 readouts, indicating future value creation. Concerns exist regarding increased full-year net loss and cash burn.
• Patients: Significant positive impact with potential for new, first-in-class therapies for underserved genetic conditions (LGMD2I/R9, ADH1, achondroplasia). Attruby continues to provide a differentiated treatment option for ATTR-CM.
• Prescribers: Attruby's clinical differentiation and growing prescription base indicate strong adoption. New therapies, if approved, will provide additional treatment tools for rare genetic conditions.
• Employees: Continued growth and pipeline success suggest job stability and potential for expansion. New hires in key commercial roles indicate strategic investment in future launches.
• Creditors: The issuance of convertible notes extends debt maturity and aims to lower interest expense, which is favorable for creditors.

Next Steps

• Share new OLE data for Acoramidis at ACC Scientific Sessions in March 2026 and in additional medical congresses throughout 2026.
• Submit NDA to FDA for BBP-418 in 1H 2026.
• Engage regulatory agencies to identify an expedited path to approval for BBP-418 in Europe.
• Initiate clinical studies of BBP-418 in LGMD2I/R9 for individuals less than 12 years of age and in LGMD2M/2U in the near future.
• Submit NDA to FDA for encaleret in ADH1 in 1H 2026.
• Submit Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for encaleret in ADH1.
• Initiate RECLAIM-HP, a Phase 3 study of encaleret in chronic hypoparathyroidism in 2H 2026.
• Submit NDA to FDA and MAA to EMA for infigratinib in achondroplasia in 2H 2026.
• Accelerate the development of infigratinib for hypochondroplasia, with Phase 2 data expected in 2H 2026.
• Submit IND to the FDA for Depleter for ATTR-CM in 2027.

Key Dates

Recommendation

The company demonstrated strong commercial execution with Attruby, achieving significant revenue growth and market penetration. More importantly, the successful Phase 3 readouts for three distinct pipeline assets (infigratinib, BBP-418, encaleret) in a short period significantly de-risk the company's future growth trajectory and validate its drug development model. These assets address substantial unmet medical needs and have the potential to be first-in-class therapies, positioning BridgeBio for multiple product launches in the near future. While the company reported an increased net loss for the full year and higher operating expenses, these are largely attributable to strategic investments in commercialization and R&D for a robust pipeline. The recent convertible note issuance also strengthens the balance sheet for upcoming commercialization efforts. The combination of current commercial success and a de-risked, late-stage pipeline suggests strong future revenue potential and justifies a "buy" recommendation for long-term investors.

Keywords

BridgeBio Pharma, BBIO, financial results, Q4 2025, full year 2025, Attruby, acoramidis, ATTR-CM, transthyretin amyloid cardiomyopathy, infigratinib, achondroplasia, BBP-418, LGMD2I/R9, limb-girdle muscular dystrophy, encaleret, ADH1, autosomal dominant hypocalcemia, rare pediatric disease, PRV, Phase 3 trials, NDA submission, biopharmaceutical, genetic conditions, drug development